Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J05AR17

Emtricitabine / Tenofovir alafenamide Viatris(emtricitabine;tenofovir alafenamide fumarate)

HIV Infections

Marketing Authorisation Holder: Viatris Limited

EMA Authorisation: 18/07/2025

INN: emtricitabine;tenofovir alafenamide

Indication

Emtricitabine/Tenofovir alafenamide Viatris is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Emtricitabine / Tenofovir alafenamide Viatris — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.